Renaissance Technologies’s Werewolf Therapeutics HOWL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$430K Sell
516,218
-161,548
-24% -$111K ﹤0.01% 2664
2025
Q4
$429K Buy
677,766
+221,766
+49% +$270K ﹤0.01% 2634
2025
Q3
$898K Buy
456,000
+139,700
+44% +$191K ﹤0.01% 2542
2025
Q2
$345K Buy
316,300
+252,400
+395% +$260K ﹤0.01% 2993
2025
Q1
$62.1K Buy
63,900
+7,000
+12% +$9.17K ﹤0.01% 3266
2024
Q4
$84.2K Sell
56,900
-95,300
-63% -$194K ﹤0.01% 3311
2024
Q3
$323K Sell
152,200
-18,800
-11% -$42.8K ﹤0.01% 2955
2024
Q2
$417K Buy
171,000
+86,800
+103% +$417K ﹤0.01% 2781
2024
Q1
$546K Sell
84,200
-23,306
-22% -$136K ﹤0.01% 2823
2023
Q4
$415K Buy
107,506
+62,306
+138% +$159K ﹤0.01% 2854
2023
Q3
$97K Buy
45,200
+2,300
+5% +$6.34K ﹤0.01% 3254
2023
Q2
$131K Buy
42,900
+8,800
+26% +$24.8K ﹤0.01% 3408
2023
Q1
$89K Sell
34,100
-44,123
-56% -$132K ﹤0.01% 3525
2022
Q4
$160K Buy
78,223
+59,923
+327% +$157K ﹤0.01% 3490
2022
Q3
$83K Buy
18,300
+1,500
+9% +$8.14K ﹤0.01% 3650
2022
Q2
$69K Buy
+16,800
New +$76.7K ﹤0.01% 3935

Other funds holding HOWL

Renaissance Technologies's HOWL Position: Q1 2026 in Review

Renaissance Technologies reduced its Werewolf Therapeutics (HOWL) stake by 24% in Q1 2026, selling an estimated $111K and leaving 516,218 shares worth $430K. The position accounts for ﹤0.01% of the portfolio, ranked #2664.

Renaissance Technologies first reported a position in HOWL in Q2 2022 and has held it in 16 quarters since. The position peaked at $898K in Q3 2025. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Renaissance Technologies held 516,218 shares of Werewolf Therapeutics worth $430K as of Q1 2026.
  • Renaissance Technologies sold 161,548 Werewolf Therapeutics shares in Q1 2026, an estimated $111K.
  • Werewolf Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2664 holding.
  • Renaissance Technologies first reported a position in Werewolf Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • Renaissance Technologies's Werewolf Therapeutics position peaked at $898K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.